Hjem › Melanom › Minnesota › Rochester
Kliniske studier for Melanom i Rochester, MN
16 studier for Melanom søker deltakere på steder i og rundt Rochester (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RekruttererFase 2
- Mayo Clinic in Rochester, Rochester
Pan-tumor MRD Study
RekruttererObservasjonsstudie
- Mayo Clinic, Rochester
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
RekruttererFase 2
- Local Institution - 0129, Rochester
- Local Institution - 0174, Rochester
- Local Institution - 0181, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RekruttererObservasjonsstudie
- Mayo Clinic (Rochester), Rochester
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
RekruttererFase 1
- Mayo Clinic - Rochester, Rochester
Project: Every Child for Younger Patients With Cancer
RekruttererObservasjonsstudie
- Mayo Clinic in Rochester, Rochester
Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App
RekruttererObservasjonsstudie
- Mayo Clinic in Rochester, Rochester
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
Rekrutterer
- Mayo Clinic in Rochester, Rochester
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
RekruttererObservasjonsstudie
- Mayo Clinic in Rochester, Rochester
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
RekruttererFase 1/2
- Mayo Clinic Rochester, Rochester
Neoadjuvant Darovasertib in Primary Uveal Melanoma
RekruttererFase 3
- Mayo Clinic - PPDS, Rochester
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RekruttererFase 2/3
- Mayo Clinic Rochester, Rochester
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RekruttererObservasjonsstudie
- Mayo Clinic, Rochester
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
RekruttererFase 3
- Mayo Clinic Minnesota, Rochester
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
RekruttererFase 3
- Mayo Clinic, Rochester
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RekruttererFase 1/2
- Mayo Clinic in Minnesota, Rochester
Melanom-studier i andre byer
- Houston, TX59 studier
- New York City, NY38 studier
- Los Angeles, CA34 studier
- Nashville, TN33 studier
- Pittsburgh, PA31 studier
- Boston, MA26 studier
- Philadelphia, PA23 studier
- San Francisco, CA22 studier
- Atlanta, GA21 studier
- Durham, NC21 studier
- St. Louis, MO21 studier
- Columbus, OH21 studier
Andre studier i Rochester
- Brystkreft42 studier
- Ikke-småcellet lungekreft37 studier
- Metastatisk kreft31 studier
- Kreft (alle typer)30 studier
- Kolorektal kreft29 studier
- Eggstokkreft29 studier
- Multipelt myelom24 studier
- Prostatakreft22 studier
- Hjertesvikt22 studier
- Pankreaskreft22 studier
- Lungekreft20 studier
- Endometriekreft20 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.